期刊
JOURNAL OF CLINICAL MEDICINE
卷 12, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/jcm12020560
关键词
oral squamous cell carcinoma; hypoxia; HIF-1 alpha; perfluorocarbons; tumor microenvironment
Hypoxia in solid tumors affects tumor therapy, but targeting the hypoxic tumor microenvironment shows promise. In this study, a drug carrier was developed to alleviate hypoxia and inhibit the growth of oral squamous cell carcinoma (OSCC).
As a typical hallmark of solid tumors, hypoxia affects the effects of tumor radiotherapy, chemotherapy, and photodynamic therapy. Therefore, targeting the hypoxic tumor microenvironment (TME) is a promising treatment strategy for cancer therapy. Here, we prepared an Albumin Human Serum (HSA)-coated perfluorocarbon (PFC) carrying oxygen (PFC@O-2) to minimize OSCC hypoxia. The results showed that PFC@O-2 significantly downregulated the expression of HIF-1 alpha and the number of M2-like macrophages in vitro. Furthermore, PFC@O-2 effectively inhibited the growth of oral squamous cell carcinoma (OSCC) and reduced the proportion of negative immunoregulatory cells, including myeloid-derived suppressor cells (MDSCs) and M2-like macrophages of TME in a 4-nitroquinoline N-oxide (4NQO)-induced mouse model. Conversely, the infiltration of CD4(+) and CD8(+) T cells was significantly increased in TME, suggesting that the anti-tumor immune response was enhanced. However, we also found that hypoxia-relative genes expression was positively correlated with CD68(+)/CD163(+) TAMs in human tissue specimens. In summary, PFC@O-2 could effectively inhibit the progression of OSCC by alleviating hypoxia, which provides a practical basis for gas therapy and gas synergistic therapy for OSCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据